Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Jeevan Scientific Technology's Net Margin % or its related term are showing as below:
BOM:538837'
s Net Margin % Range Over the Past 10 Years
Min: -34.48 Med: 1.21 Max: 24.73
Current: -0.26
BOM:538837's Net Margin % is ranked better than 71.23% of 942
companies
in the Biotechnology industry
Industry Median: -89.445
vs BOM:538837: -0.26
Jeevan Scientific Technology (BOM:538837) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Jeevan Scientific Technology Net Margin % Related Terms
Jeevan Scientific Technology Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:538837 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Jeevan Scientific Technology's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jeevan Scientific Technology Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jeevan Scientific Technology's Net Margin % distribution charts can be found below:
* The bar in red indicates where Jeevan Scientific Technology's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jeevan Scientific Technology (BOM:538837) has a Net Margin % of 7.55% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Jeevan Scientific Technology and its competitors. This is 524% above median its historical median of 1.21. According to the industry distribution chart, Jeevan Scientific Technology ranks #271 out of 942 companies in the Biotechnology industry, placing it in the top 28.8%.
Is Jeevan Scientific Technology's Net Margin % too high?
Jeevan Scientific Technology's current Net Margin % of 7.55% is 524% above median its 10-year median of 1.21. Based on the distribution chart, Jeevan Scientific Technology ranks #271 out of 942 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Jeevan Scientific Technology has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jeevan Scientific Technology's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jeevan Scientific Technology ranks #271 out of 942 companies for Net Margin %. This puts Jeevan Scientific Technology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Jeevan Scientific Technology and its competitors. Jeevan Scientific Technology's current Net Margin % is 7.55%, which is 524% above median its own 10-year median of 1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jeevan Scientific Technology stock overvalued right now?
Based on GuruFocus' analysis, Jeevan Scientific Technology (BOM:538837) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹61.75, compared to a current price of ₹72.77 — trading 17.8% above its estimated fair value. The current Net Margin % is 7.55%, which is 524% above median its 10-year median of 1.21. Jeevan Scientific Technology's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Jeevan Scientific Technology (BOM:538837), the current Net Margin % is 7.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jeevan Scientific Technology (BOM:538837) Overvalued in 2026?
Based on GuruFocus' analysis, Jeevan Scientific Technology stock appears to be overvalued.
The current stock price of ₹72.77 is trading 17.8% above its estimated GF Value™ of ₹61.75.
GuruFocus considers Jeevan Scientific Technology to be Modestly Overvalued.
Key valuation signals for BOM:538837:
Net Margin %: 7.55% (524% above median its 10-year median of 1.21)
GF Value™: ₹61.75 vs. price of ₹72.77 (17.8% above fair value)
No single metric tells the full story. See the BOM:538837 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jeevan Scientific Technology Ltd is an India-based company engaged in providing clinical research and data management services. Jeevan Scientific is an independent clinical contract research organization, offering reliable, cost-effective, and technology-driven clinical research solutions to various clients across the globe. Its services offer high-value testing services, including bioanalytical services for small and large molecules, ranging across generics, biosimilars, and other new drugs. It operates in a single segment, namely clinical research services.
65GF Score
Get the complete analysis for BOM:538837
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:538837 has been successfully added to your 
